FibroBiologics Inc. (FBLG)

FibroBiologics Inc. stands at the forefront of innovative biopharmaceutical advancements, dedicated to the development and commercialization of fibroblast cell-based therapies tailored to address the complex needs of patients grappling with chronic diseases. Established just two years ago, FibroBiologics has swiftly emerged as a pioneering force in the field, fueled by a commitment to harnessing the immense potential of fibroblast cell-based therapies to revolutionize the treatment landscape. At the heart of FibroBiologics' groundbreaking approach is its proprietary fibroblast platform, a cornerstone for the development of biologic cures and treatments spanning a spectrum of chronic diseases. The company's focus extends to conditions such as degenerative disc disease, multiple sclerosis, wound healing, cancer, and anti-aging applications, including thymic involution reversal and splenic involution reversal. With a robust intellectual property portfolio, FibroBiologics currently holds over 150 U.S. and international issued/pending patents, covering diverse clinical pathways. These pathways include multiple sclerosis, cartilage repair, degenerative disc disease, cancer, wound healing, and extension of life programs, underscoring the company's commitment to pioneering solutions across various medical fronts. In a significant move to propel its mission forward, FibroBiologics successfully completed a private placement from April to September 2023, issuing around 75,000 of its Series B-1 preferred shares priced between $18 and $20 per share. With an impending direct listing, all outstanding Series B and B-1 preferred stock will seamlessly convert to common stock.